Contributions of symptomatic osteoarthritis and physical function to incident cardiovascular disease by Corsi, Michela et al.
RESEARCH ARTICLE Open Access
Contributions of symptomatic osteoarthritis
and physical function to incident
cardiovascular disease
Michela Corsi1, Carolina Alvarez2, Leigh F. Callahan2,3, Rebecca J. Cleveland2,3, Yvonne M. Golightly2,4,5,
Joanne M. Jordan2,3, Amanda E. Nelson2,3, Jordan Renner2,6, Allen Tsai1 and Kelli D. Allen2,3,7*
Abstract
Background: Osteoarthritis (OA) is associated with worsening physical function and a high prevalence of comorbid
health conditions. In particular, cardiovascular disease (CVD) risk is higher in individuals with OA than the general
population. Limitations in physical function may be one pathway to the development of CVD among individuals
with OA. This study evaluated associations of symptomatic knee OA (sxKOA), baseline physical function and worsening
of function over time with self-reported incident CVD in a community-based cohort.
Methods: Our sample consisted of individuals from the Johnston County Osteoarthritis Project who did not report
having CVD at baseline. Variables used to evaluate physical function were the Health Assessment Questionnaire (HAQ),
time to complete 5 chair stands, and the 8-ft walk. Worsening function for these variables was defined based on
previous literature and cutoffs from our sample. Logistic regression analyses examined associations of sxKOA, baseline
function and worsening of function over time with self-reported incident CVD, unadjusted and adjusted for relevant
demographic and clinical characteristics.
Results: Among 1709 participants included in these analyses, the mean age was 59.5 ± 9.5 years, 63.6% were women,
15% had sxKOA, and the follow up time was 5.9 ± 1.2 years. About a third of participants reported worsening HAQ
score, about two-fifths had worsened chair stand time, half had worsened walking speed during the 8-ft walk, and
16% self-reported incident CVD. In unadjusted analyses, sxKOA, baseline function, and worsening function were all
associated with self-reported incident CVD. In multivariable models including all of these variables, sxKOA was not
associated with incident CVD, but worsening function was significantly associated with increased CVD risk, for all
three functional measures: HAQ odds ratio (OR) = 2.49 (95% confidence interval (CI) 1.90–3.25), chair stands OR = 1.58
(95% CI 1.20–2.08), 8-ft walk OR = 1.53 (95%CI 1.15–2.04). These associations for worsening function remained in
models additionally adjusted for demographic and clinical characteristics related to CVD risk.
Conclusions: The association between symptomatic knee osteoarthritis and cardiovascular disease risk was explained
by measures of physical function. This highlights the importance of physical activity and other strategies to prevent
functional loss among individuals with symptomatic knee osteoarthritis.
Keywords: Osteoarthritis, Function, Cardiovascular disease
* Correspondence: kdallen@email.unc.edu
2Thurston Arthritis Research Center, University of North Carolina at Chapel
Hill, 3300 Thurston Bldg., CB# 7280, Chapel Hill, NC 27599, USA
3Department of Medicine, University of North Carolina at Chapel Hill, 125
MacNider Hall CB# 7005, Chapel Hill, NC 27599, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Corsi et al. BMC Musculoskeletal Disorders          (2018) 19:393 
https://doi.org/10.1186/s12891-018-2311-4
Background
Osteoarthritis (OA) is a key contributor to functional dis-
ability that is becoming increasingly prevalent worldwide
[1]. Symptomatic knee OA (sxKOA) is associated with
functional limitations, which tend to worsen over time [2,
3]. Individuals with OA also have a significantly increased
risk of cardiovascular disease (CVD) [4–6]. Individuals
with OA tend to have multiple risk factors for CVD, in-
cluding increased body mass index (BMI), hypertension,
physical inactivity, and nonsteroidal anti-inflammatory
drug (NSAID) use [5, 7]. For this reason, many hypotheses
have been proposed regarding underlying pathophysio-
logical mechanisms connecting OA and CVD, including
the role of common molecular or metabolic pathways,
chronic low-grade inflammation leading to both condi-
tions, and the development of functional limitations from
OA that in turn leads to a lack of physical activity, exacer-
bating both conditions [7, 8].
Recently, a number of studies have shown an association
between physical function and CVD among individuals
with OA. Schieir et al. showed that there was a greater risk
of CVD in women with arthritis (with participants primar-
ily having OA), compared to women without arthritis; the
risk of CVD was further increased in women with both
arthritis and physical limitations [9]. Among men in this
study, there was only an increased risk of incident CVD
for those who reported both arthritis and physical limita-
tions. Together these results suggest that physical function
may play a significant role in the development of CVD in
patients with arthritis. While this study focused broadly
on arthritis, another cohort study found that the relation-
ship between sxKOA and CVD was sustained when con-
trolling for age, obesity, and metabolic factors, yet became
insignificant when controlling for functional limitations
[10]. However, this was a cross-sectional study, so a causal
relationship could not be established. Another cohort
study found that individuals with hip or knee OA who
used a walking aid due to functional disability had a 30%
greater risk of developing CVD than those who did not
use a walking aid [11]. Another recent longitudinal cohort
study found a dose-response relationship between the
number of joints with OA and CVD risk; however, this re-
lationship became non-significant when controlling for
difficulty walking [12].
The purpose of this study was to examine associations of
sxKOA, baseline physical function and worsening of func-
tion over time with self-reported incident CVD in a
community-based cohort. In particular, we were interested
in understanding whether different measures of physical
function explained any relationship between sxKOA and
CVD risk. This study adds to the literature in several im-
portant ways. First, it is one of few studies to examine the
association between OA and CVD risk in a longitudinal
analysis. Second, this study has multiple measures of
function, including performance-based measures, which to
our knowledge have not been used in other longitudinal
studies of this topic. This deepens our understanding of
how various functional measures may serve as predictors
of CVD among individuals with OA. Third, this study ex-
amined not only baseline function but also change in func-
tion over time; prior studies have not assessed the role of
worsening function over time and how this may play in the
development of CVD in individuals with OA.
Methods
Participants
This study involved participants in the Johnston County
Osteoarthritis Project (JoCo OA), an ongoing community-
based study focusing on hip and knee OA in a rural
population [13]. Participants were civilian,
non-institutionalized African-American and Caucasian
adults aged 45 years and older selected from six townships
within Johnston County, North Carolina. Initial enroll-
ment occurred from 1991 to 1997 (Original Cohort), with
first follow-up of this cohort occurring from 1999 to 2003.
A second wave of enrollment occurred in 2003–2004
(Enrichment Cohort), aimed at enriching the sample for
AA and younger individuals. First follow-up of this group
occurred from 2006 to 2011. This research was reviewed
and approved by the Institutional Review Board of the
University of North Carolina, Chapel Hill; all participants
provided written informed consent.
From participants enrolled in the Original Cohort
(N = 3249) and Enrichment Cohort (N = 1141), we ex-
cluded individuals who did not have baseline clinic data,
follow-up clinic data (due to loss to follow-up), and base-
line and follow-up knee OA and CVD status. Then those
who self-reported having CVD at baseline were excluded
(Fig. 1). Finally, we excluded individuals who were missing
baseline or follow-up data for functional tests or covari-
ates, leading to a final sample size of 1709. Complete case
analysis (CCA) was used so that only participants with
non-missing baseline covariates and physical function sta-
tus at baseline and follow-up were analyzed. This propor-
tion of participant with missing baseline or follow-up data
for analyses was 4.9%, so the impact of bias from their re-
moval is likely to be small and CCA can be conducted re-
gardless of the missing data pattern (Fig. 1) [14].
Measures
Outcome: Incident self-report CVD
Incident CVD was assessed at first follow-up through
self-report. The definition of CVD was based on the
World Health Organization criteria; due to changes in
these criteria, self-report items differed slightly at differ-
ent time points. For the Original Cohort, CVD at first
follow-up was defined as having a heart attack, stroke, cir-
culation or other heart problem. For the Enrichment
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Cohort, the incident CVD definition at first follow-up was
expanded to include angina and congestive heart failure.
Symptomatic knee OA
JoCo OA participants had anteroposterior (Original Cohort
enrollment) or posteroanterior (Enrhichment Cohort
enrollment) radiographs taken of both knees while
weight-bearing using a Synaflexer® positioning device. All
radiographs were read for Kellgren-Lawrence (K-L) score
by a single bone and joint radiologist (JBR) without regard
to participant’s clinical status. Intrarater reliability and inter-
rater reliability, assessed with another trained radiologist,
were both high (weighted kappas were 0.89 and 0.86, re-
spectively). For the purpose of this study, radiographic
KOA was defined as a K-L grade ≥ 2. To assess joint symp-
toms, participants were asked: “On most days, do you have
pain, aching, or stiffness in your…right/left knee.” Partici-
pants responding “yes” to this question for a joint with
radiographic OA were considered to have sxKOA.
Function measures
We included three measures of physical function: chair
stands, 8-ft walk, and the Health Assessment Question-
naire Disability Index (HAQ).
Health assessment questionnaire The HAQ is a meas-
ure of self-reported disability, assessing ability to per-
form typical eight daily tasks (dressing, arising, eating,
walking, reaching, gripping, chores, and hygiene) during
the past 7 days [15]. Answers for each question are
scored from 0 to 3, with 0 being no disability and 3 be-
ing complete disability. Per scoring guidelines, mean
HAQ score was calculated for each participant if six or
more of the eight categories were non-missing. We
categorized baseline mean HAQ as follows: HAQ = 0,
0 < HAQ< 1, or HAQ ≥ 1, based on definitions previously
used with JoCo OA data [16]. Based on the previously
established minimum clinically important difference in
HAQ score [15, 17, 18], we defined a clinically significant
change as baseline +/− 0.22; individuals whose baseline
scores rose by 0.22 or more were classified as worsening,
and those whose baseline scores fell by 0.22 or more were
classified as improving. If change in speed did not meet
these values, participants were classified as having stayed
the same. The groups were then dichotomized into im-
proved/stayed the same, or worsened.
Chair stands Based on previously established protocols
[19, 20], we assessed time for participants to complete 5
chair stands. Participants were seated in a chair with feet
Fig. 1 Flow Chart of Participants Included in Analyses
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touching the floor and asked to rise without the use of
arms as support. To ensure this, participants were asked
to cross their arms at their wrists and hold them tight to
their chests throughout the test. Participants who were
unable to rise from a chair by themselves or scoot for-
ward or stand up without using their arms were classi-
fied being unable to complete this test. For those able to
perform this task, time taken to complete the 5 chair
stands was recorded in seconds. We then categorized
times into quartiles, based on baseline scores of those
without sxKOA in our study sample. These thresholds
were also determined separately for males and females
due to evidence of differences in performance between
these two groups [21]. For males, these cutoffs were
time < 8.4 s (quartile 1, Q1), 8.4 s < time < 10.2 s (quartile
2, Q2), 10.2 s < time < 12.9 s (quartile 3, Q3), 12.9 s <
time (quartile 4, Q4), or unable to complete all five chair
stands. For females, these cutoffs were time < 9.0 s (Q1),
9.0 s < time < 11.3 s (Q2), 11.3 s < time < 14.1 s (Q3),
14.1 s < time (Q4), or unable to complete all five chair
stands. We then categorized participants as either having
worsened (moved up a quartile from baseline) or stayed
the same / improved (remained in the same quartile or
moved down a quartile from baseline) at the time of first
follow-up. Participants unable to complete the chair
stands at baseline were categorized as follows: staying
the same / improving if they became able to complete at
follow-up and worsening if they remained unable to
complete at follow-up.
8-foot walk Using previously established procedures
[20, 22], participants were asked to perform two trials in
which they walked the 8-ft at their normal pace; times of
the two trials were averaged and converted to gait speed
(m/s) and kept continuous for the baseline measure. We
categorized participants as either worsening or staying
the same/improving in gait speed at follow-up. We de-
fined worsening as a decrease of 0.1 m/s based on previ-
ous literature suggesting this may be a clinically relevant
decline [23, 24].
Covariates Variables that could potentially confound the
associations between sxKOA, function and CVD were
included in multivariable models. These included: base-
line enrollment group (Original vs. Enrichment cohort),
age, gender, race (African American vs. Caucasian), edu-
cation (< high school vs. ≥ high school), body mass
index (BMI), waist to hip ratio (WHR), self-reported
presence of diabetes, hypertension, or high cholesterol,
and self-reported nonsteroidal anti-inflammatory drugs
(NSAIDs) use at baseline. BMI, diabetes mellitus, hyper-
tension and high cholesterol are often considered as-
pects of metabolic syndrome. These variables were
included in our model as previous research has indicated
there may be underlying metabolic contributions to the
development of comorbid CVD in individuals with OA
[8]. NSAID use was also chosen as a possible confounder
as it too has been indicated as a possible contributor to in-
creased CVD risk in individuals with OA [7].
Statistical analysis
Descriptive statistics were calculated for all participants
in the final analytic sample. Logistic regression models
were used to model the odds of incident CVD. These
population-averaged models for non-normal (binomial)
measures were fit to each of the three physical function
measure analyses. First, unadjusted odds ratios (OR) and
95% confidence intervals (CI) were computed to exam-
ine associations of sxKOA, baseline function, and wors-
ening function with incident CVD. Second, multivariable
models that jointly examined associations of sxKOA,
baseline function and worsening function with incident
CVD (Model 1) were conducted. Third, multivariable
models that included Model 1 variables along with rele-
vant demographic and health covariates (Model 2) were
conducted. Models 1 and 2 were assessed for the inter-
action of sxKOA with physical function (both the base-
line measure and the follow-up worsening indicator) at
the 0.05 significance level. All statistical computations
were performed using SAS, version 9.4 (Cary, NC).
Results
Participant characteristics are summarized in Table 1.
Almost a quarter of our sample consisted of the Enrich-
ment cohort, and overall mean time to follow-up was
5.9 ± 1.2 years. The sample comprised 63.6% women,
27.8% African Americans, and 25.9% with less than a high
school education, while mean age of participants was 59.5
± 9.5 years. The mean BMI was 29.3 ± 6.0 kg/m2, with
over three quarters of participants being overweight
(38.2%) or obese (38.4%). At baseline, approximately a
tenth of participants had diabetes, a third had hyperten-
sion, a fifth had high blood cholesterol, and almost a third
reported NSAID use. Baseline sxKOA was present for ap-
proximately 15% of participants, and approximately 16%
of participants developed CVD by their first follow-up.
Individuals with sxKOA at baseline had 1.50 times the un-
adjusted odds of incident CVD (95% CI 1.08–2.08).
HAQ
Regarding mean HAQ scores, over half of participants
(58.6%) had a score of zero, almost a third (30.8%) had
0 < HAQ < 1, and about a tenth (10.6%) had 1 ≤HAQ at
baseline. About a third (33.0%) of participants worsened
by 0.22 units or more in mean HAQ score by first
follow-up (which corresponds to the minimum clinically
important difference), with the remainder staying the
same or improving.
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There were no significant interactions of sxKOA with
baseline or worsening HAQ scores, so overall main ef-
fects are reported (Table 2). In unadjusted analyses, par-
ticipants with baseline HAQ scores > 0 had 30–90%
higher odds of incident CVD compared to those with
HAQ = 0; those with worsening HAQ scores over time
had 2.5 times greater odds of incident CVD. In multivar-
iable Model 1, baseline HAQ score ≥ 1 and worsening
HAQ continued to have significantly greater odds of in-
cident CVD, but sxKOA was no longer significantly as-
sociated with CVD risk in this model. These associations
were similar in the fully adjusted model (Model 2), in
which age and self-reported diabetes were also associ-
ated with incident CVD.
Chair stands
For chair stands, 5.4% of participants were unable to
complete the test at baseline, and the quartile cutoff dis-
tribution (fastest to slowest times) was 20.5%, 23.1%,
23.5 and 27.5%. About 42% of participants worsened by
moving up a quartile (or becoming unable) in chair
stand performance at follow-up, with the remaining
staying the same or improving.
There were no significant interactions of sxKOA with
baseline or worsening chair stand time and so overall
main effects are reported (Table 3). Compared to partici-
pants in the lowest quartile (Q1) of chair stand time,
those in higher quartiles (Q2, Q3, and Q4) and those un-
able to complete the test had significantly elevated un-
adjusted odds of incident CVD; worsening chair stand
performance over time was also associated with in-
creased incident CVD. In multivariable Model 1, similar
associations with incident CVD remained for baseline
chair stand quartiles and worsening chair stand time,
but sxKOA was no longer significantly associated with
incident CVD risk in this model. These associations
were similar in the fully adjusted model (Model 2), al-
though inability to complete chair stands was no longer
significantly associated with incident CVD risk; sex and
diabetes were also associated with increased CVD risk.
8-foot walk
The mean baseline gait speed during the 8-ft walk was
0.87 m/s (SD = 0.26). About half (49.6%) of participants
worsened by decreasing 0.1 m/s or more in mean gait
speed by first follow-up. The measure of baseline gait
speed showed a significant interaction with baseline
sxKOA status, so effects of baseline gait speed are
shown separately for participants without and with
sxKOA (Table 4). Results for baseline gait speed are pre-
sented in units of 0.3 m/s difference; this was selected
because it approximated 1 standard deviation for the
distribution of baseline gait speeds. For participants
without sxKOA, unadjusted odds of incident CVD were
higher for those with a slower gait speed at baseline. In
contrast, for participants with sxKOA, baseline gait
speed was not associated with incident CVD. In un-
adjusted analyses, there was no association between
worsening gait speed and incident CVD.
Table 1 Descriptive Characteristics of Study Sample (N = 1709)
Characteristic Mean (SD) or %
Baseline
% Original cohort 75.6
Demographic
Mean (SD) Age 59.5 (9.5)
% Women 63.6
% African American 27.8
% with < 12 Years Education 25.9
Health Related
Mean (SD) Body Mass Index (kg/m2) 29.3 (6.0)
Mean (SD) Waist to Hip Ratio 0.87 (0.09)
% Hypertension 32.9
% Diabetes 8.7
% High cholesterol 20.8
OA Related
% Non-steroidal Anti-inflammatory Drug Use 31.5
% Symptomatic Osteoarthritis 15.4
Function Related
Mean Health Assessment Questionnaire; HAQ (SD) 0.27 (0.47)
% 0 = HAQ 58.6
% 0 < HAQ < 1 30.8
% 1≤ HAQ 10.6
Mean (SD) Speed During 8 ft. Walk (m/s) 0.87 (0.26)
Mean (SD) Chair Stand Times (s) 12.2 (4.8)
% Q1a 20.5
% Q2 23.1
% Q3 23.5
% Q4 27.5
% Unable to Complete 5.4
Follow-up
Mean (SD) years to follow-up 5.9 (1.2)
% Worsened HAQ 33.0
% Worsened 8 ft. Walk speed 49.6
% Worsened Chair Stand Time 42.2
% Incident Cardiovascular Disease 15.9
a5 Chair stand time quartlies defined from the non-exposure subsample without
sxKOA at baseline: Males: Q1 (time < =8.4 s), Q2 (8.4 s < time < =10.2 s), Q3
(10.2 s < time < =12.9 s), Q4 (12.9 s < time)"; Females: Q1 (time < =9.0 s), Q2 (9.0 s
< time < =11.3 s), Q3 (11.3 s < time < =14.1 s), Q4 (14.1 s < time)
SD standard deviation, OA Osteoarthritis
Corsi et al. BMC Musculoskeletal Disorders          (2018) 19:393 Page 5 of 9
Table 2 Unadjusted and Adjusted Associations of sxKOA and HAQ Scores with Incident CVD
Variable Unadjusted Model 1a Model 2a
OR (95% CI) OR (95% CI) OR (95% CI)
sxKOA vs. no sxKOA at baseline 1.50 (1.08, 2.08) 1.14 (0.80, 1.61) 1.10 (0.76, 1.61)
Baseline 0 < HAQ < 1 vs. HAQ = 0 1.29 (0.97, 1.72) 1.17 (0.87, 1.57) 1.08 (0.79, 1.47)
Baseline 1≤ HAQ vs. HAQ = 0 1.94 (1.32, 2.85) 1.91 (1.27, 2.86) 1.82 (1.18, 2.79)
Worsened HAQ vs. unchanged or improved 2.51 (1.93, 3.27) 2.49 (1.90, 3.25) 2.35 (1.79, 3.10)
Age: 1 year increase 1.02 (1.00, 1.03)
Gender: Female vs. Male 1.28 (0.91, 1.80)
Race: Black vs. White 1.13 (0.83, 1.54)
Education: <HS vs. HS or greater 0.89 (0.65, 1.24)
Cohort: Enrichment vs. Original 0.96 (0.69, 1.33)
BMI: 1 kg/m2 increase 0.98 (0.95, 1.00)
WHR: 0.1 unit increase 1.15 (0.98, 1.36)
Diabetes vs. not 1.84 (1.21, 2.80)
Hypertension vs. not 1.10 (0.81, 1.48)
High cholesterol vs. not 1.03 (0.74, 1.44)
NSAIDs vs. not 1.27 (0.94, 1.71)
CI confidence interval, sxKOA symptomatic knee osteoarthritis, HAQ health assessment questionnaire, HS high school, BMI body mass index, WHR waist-to-hip
ratio, NSAIDs non-steroidal anti-inflammatory drugs
aModels 1 and 2 are adjusted for all variables with data listed in the column
Table 3 Unadjusted and Adjusted Associations of sxKOA and Chair Stands with Incident CVD
Variable Unadjusted Model 1a Model 2a
OR (95% CI) OR (95% CI) OR (95% CI)
sxKOA vs. no sxKOA at baseline 1.50 (1.08, 2.08) 1.28 (0.90, 1.80) 1.24 (0.86, 1.79)
Baseline 5 chair stand time Q2 vs. Q1** 1.77 (1.14, 2.75) 1.82 (1.17, 2.83) 1.77 (1.13, 2.78)
Baseline 5 chair stand time Q3 vs. Q1** 1.93 (1.25, 2.98) 2.04 (1.31, 3.16) 1.79 (1.14, 2.81)
Baseline 5 chair stand time Q4 vs. Q1** 1.85 (1.21, 2.82) 2.02 (1.30, 3.15) 1.65 (1.02, 2.65)
Baseline 5 chair stand time unable vs. Q1** 2.50 (1.36, 4.58) 2.14 (1.16, 3.98) 1.71 (0.89, 3.27)
Worsened 5 Chair stand time vs. unchanged or improved 1.50 (1.15, 1.94) 1.58 (1.20, 2.08) 1.45 (1.09, 1.93)
Age: 1 year increase 1.01 (1.00, 1.03)
Gender: Female vs. Male 1.46 (1.05, 2.04)
Race: Black vs. White 1.11 (0.82, 1.52)
Education: <HS vs. HS or greater 0.95 (0.68, 1.31)
Cohort: Enrichment vs. Original 1.06 (0.77, 1.47)
BMI: 1 kg/m2 increase 0.98 (0.96, 1.01)
WHR: 0.1 unit increase 1.16 (0.99, 1.36)
Diabetes vs. not 1.91 (1.26, 2.89)
Hypertension vs. not 1.13 (0.84, 1.52)
High cholesterol vs. not 1.03 (0.74, 1.44)
NSAIDs vs. not 1.30 (0.97, 1.74)
CI confidence interval, Q quarter, sxKOA symptomatic knee osteoarthritis, HS high school, BMI body mass index, WHR waist-to-hip ratio, NSAIDs non-steroidal
anti-inflammatory drugs
aModels 1 and 2 are adjusted for all variables with data listed in the column
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In multivariable Model 1, slower baseline gait speed
remained associated with incident CVD only for those
without sxKOA. Worsening gait speed was also associ-
ated with incident CVD in Model 1. These associations
were similar in the fully adjusted Model 2, in which
NSAID use and self-reported diabetes were also associ-
ated with incident CVD.
Discussion
In this analysis, we examined the unique contributions
of sxKOA, baseline function and worsening of function
with incident CVD risk. With respect to sxKOA, we
found significant associations with incident CVD risk in
unadjusted analyses, but not in multivariable analyses
adjusting for functional variables. There were significant
associations of functional variables with incident CVD
risk, and in particular, worsening of function variables
over time was consistently associated with CVD risk in
multivariable models. The association of one function
variable, 8-ft walk, differed between those with and with-
out sxKOA, being important only in the latter group.
The finding of a significant bivariate association of
sxKOA with CVD risk is in agreement with results of
prior studies [5, 10–12, 25]. Importantly, the longitu-
dinal nature of this association supports that sxKOA
predicts development of future CVD. In multivariable
analyses including function variables, even prior to ad-
justment for other confounders, sxKOA was no longer
significantly associated with CVD risk. This confirms an-
other recent longitudinal study in which the association
of number of joints with OA with CVD risk was
explained by self-reported difficulty walking at baseline
[12]. These studies indicate that function is at least one
key contributor to CVD risk among individuals with
sxOA. Knowledge of this underlying mechanism is ex-
tremely important, as it points to a potential interven-
tion approach. In particular, physical activity programs
can significantly improve functional outcomes among in-
dividuals with sxKOA [26] and therefore may confer an
important benefit regarding downstream CVD risk, par-
ticularly since physical activity also improves a number
of metabolic factors leading to CVD.
There were a number of interesting findings regarding
associations of functional measures with CVD risk. First,
it is notable that all of the function measures (with the
exception of 8-ft walk for people with sxKOA) were as-
sociated with increased CVD risk, suggesting that both
performance-based measures and self-report measures
(e.g., HAQ) may be helpful markers of CVD risk; this
adds to prior studies that have shown positive associa-
tions with self-report function measures. Second, even
when baseline function and change in function were in-
cluded in the same model, change in function consist-
ently remained significantly associated with incident
CVD risk. This also adds to prior studies, which have fo-
cused on functional status at a single time point. These
results illustrate the importance of functional decline in
the prediction of CVD, regardless of baseline functional
status, and further illustrates the importance of physical
activity programs that can slow the progression of func-
tional decline. Third, functional measures (particularly
change in function over time) continued to have
Table 4 Unadjusted and Adjusted Associations of sxKOA and 8-Foot Walk with Incident CVD
Variable Unadjusted Model 1a Model 2a
OR (95% CI) OR (95% CI) OR (95% CI)
Baseline 0.3 m/s (1SD) decrease in mean 8 ft. walk speed among those without sxKOA 1.46 (1.23, 1.74) 1.64 (1.35, 1.99) 1.46 (1.17, 1.82)
Baseline 0.3 m/s (1SD) decrease in mean 8 ft. walk speed among those with sxKOA 0.91 (0.62, 1.33) 0.99 (0.67, 1.47) 0.90 (0.59, 1.36)
Worsened 8 ft. walk vs. unchanged or improved 1.12 (0.87, 1.45) 1.53 (1.15, 2.04) 1.47 (1.07, 2.01)
Age: 1 year increase 1.01 (0.99, 1.03)
Gender: Female vs. Male 1.35 (0.96, 1.91)
Race: Black vs. White 1.05 (0.77, 1.44)
Education: <HS vs. HS or greater 0.92 (0.66, 1.27)
Cohort: Enrichment vs. Original 1.10 (0.79, 1.54)
BMI: 1 kg/m2 increase 0.98 (0.96, 1.01)
WHR: 0.1 unit increase 1.15 (0.98, 1.36)
Diabetes vs. not 1.80 (1.19, 2.71)
Hypertension vs. not 1.11 (0.83, 1.49)
High cholesterol vs. not 1.09 (0.79, 1.52)
NSAIDs vs. not 1.34 (1.00, 1.80)
CI confidence interval, Q quarter, sxKOA symptomatic knee osteoarthritis, HS high school, BMI body mass index, WHR waist-to-hip ratio, NSAIDs non-steroidal
anti-inflammatory drugs
aModels 1 and 2 are adjusted for all variables with data listed in the column
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significant associations with CVD risk even in fully ad-
justed models that included a number of factors related to
metabolic syndrome (e.g, BMI, WHR, diabetes). This is
important since metabolic syndrome has been another
proposed mechanism underlying the association between
OA and CVD [7, 8]. Kendzerska et al. also found that
self-reported walking-related disability continued to pre-
dict CVD risk even when adjusting for BMI and other
metabolic factors [12]. This evidence supports that func-
tion plays a unique role in the relationships between
sxKOA and CVD risk. Fourth, there was an interaction
between sxKOA and the 8-ft walk variable: those without
sxKOA who had worse baseline 8-ft walk speed were at a
greater risk of developing incident CVD, but for those
with sxKOA, baseline 8-ft walk performance was not a
predictor of incident CVD risk. We hypothesize this result
may be due to the fact that our sxKOA group had worse
baseline walking speeds than the non-OA group at base-
line (.75 m/s vs. 89 m/s), which confirms prior studies [27,
28]. Since walking speed was low overall among those
with sxKOA, the variability within that lower range may
not have been associated with differential CVD risk.
The association of between baseline chair stand time
categories and increased CVD risk was non-linear. Rela-
tive to participants in the best baseline chair stand cat-
egory (Q1), odds of CVD risk were elevated more for
middle categories (Q2, Q3) than for those in the worst
categories (Q4, unable to complete). However, the odds
ratios were still relatively similar (1.65–1.79 in fully ad-
justed models). The lack of completely linear relationship
may be due to the relatively small number of participants
in each baseline chair stand group.
Strengths of this study include a community-based co-
hort including African American and Caucasian men and
women, the use of both self-reported and performance-
based measures of physical function, the longitudinal
approach, and the inclusion of worsening variables for
physical function measures. However, there are several
limitations to note. First, CVD and function measures at
follow-up were assessed at a single time point; therefore,
we could not ascertain the specific time of occurrence,
and it is possible that functional decline occurred after a
CVD diagnosis or event within the follow-up period. Sec-
ond, incident CVD was assessed via self-report. Although
this method allows data for large samples to be obtained
readily and cost-effectively, this can result in less accurate
representation of true CVD. Strategies were employed in
data collection in order to maximize self-report accuracy
of CVD. These included impartial and standardized phras-
ing of the National Health Interview Survey question,
ensuring that respondents understood the question com-
pletely, and that adequate amount of time for recall was
given. However, there may still be instances of inaccurate
reporting (either over-reporting or under-reporting).
Third, the incident CVD variable definition differed some-
what between cohorts, with angina and congestive heart
only being included for the Enrichment Cohort. Fourth,
some data were missing due to loss-to-follow-up, and it is
possible that individuals with missing follow-up data were
less healthy and had more functional limitations than
those with complete data.
Conclusion
Overall, our study indicates that function is a key con-
tributor to the association between symptomatic knee
osteoarthritis and cardiovascular disease risk. Further,
worsening of function over time seems to have a particu-
larly important role. Physical activity and structured ex-
ercise programs can substantially improve function and
are already key recommendations for OA management
[26]. Unfortunately, many people with symptomatic knee
osteoarthritis remain physically inactive [29], placing
them at risk for functional loss, and perhaps subsequent
elevation of cardiovascular disease risk as a result. These
results further elevate the importance of efforts to en-
hance physical activity among individuals with symp-
tomatic knee osteoarthritis and also highlight the
importance of regular physical function assessment.
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